文献速递慢性肾脏病肾血管病与高血压

维生素D受体激活剂通过调控miR-29b与miR-30c减轻尿毒症诱导的心脏纤维化

Regulation of miR-29b and miR-30c by vitamin D receptor activators contributes to attenuate uraemia-induced cardiac fibrosis.
PubMed 文献 · Nephrol Dial Transplant · 2017-01-01

该研究在肾切除Wistar大鼠中比较骨化三醇与帕立骨化醇对尿毒症心肌纤维化的作用,发现两者均减轻心脏纤维化,帕立骨化醇组差异有统计学意义,并伴随miR-29b、miR-30c表达回升及COL1A1、MMP-2、CTGF下降;血清miR-29b、miR-30c、miR-133b在慢性肾衰竭大鼠升高且被VDRA预防。

要点

  • VDRAs可减轻尿毒症大鼠心脏纤维化,帕立骨化醇效果更显著。
  • 机制部分涉及上调miR-29b和miR-30c,抑制COL1A1、MMP-2、CTGF。
  • 血清miR-29b、miR-30c、miR-133b或可作心脏纤维化生物标志物。

核心结论

  • VDRAs尤其帕立骨化醇可减轻尿毒症诱导的心脏纤维化,部分通过调控miR-29b和miR-30c实现。
  • miR-29b、miR-30c和miR-133b可能作为心脏纤维化的血清生物标志物及潜在治疗靶点。

研究设计与样本

  • Wistar大鼠行肾切除术建立慢性肾衰竭模型,腹腔注射等效剂量的骨化三醇或帕立骨化醇。
  • 检测生化指标、心脏纤维化、心脏与血清miR-29b、miR-30c、miR-133b水平及心脏COL1A1、MMP-2、CTGF表达。

主要发现

  • 两种VDRAs均减轻心脏纤维化,帕立骨化醇治疗组差异有统计学意义。
  • 慢性肾衰竭大鼠心脏COL1A1、MMP-2、CTGF的RNA和蛋白水平升高,miR-29b和miR-30c表达降低,均被两种VDRAs减轻。
  • 慢性肾衰竭大鼠血清miR-29b、miR-30c和miR-133b显著升高,VDRA使用可预防此升高。
  • 在三种miRNA启动子中鉴定出维生素D反应元件。

临床怎么用

  • VDRAs(尤其帕立骨化醇)可能有助于减轻尿毒症心肌纤维化。
  • 血清miR-29b、miR-30c、miR-133b或可用于监测心脏纤维化,但需进一步临床验证。

局限性

  • 研究为动物实验,结论外推至人类需谨慎。
  • 样本量及具体统计值未在摘要中报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Uraemic cardiomyopathy, a process mainly associated with increased myocardial fibrosis, is the leading cause of death in chronic kidney disease patients and can be prevented by vitamin D receptor activators (VDRAs). Since some microRNAs (miRNAs) have emerged as regulators of the fibrotic process, we aimed to analyse the role of specific miRNAs in VDRA prevention of myocardial fibrosis as well as their potential use as biomarkers. METHODS: Wistar rats were nephrectomized and treated intraperitoneally with equivalent doses of two VDRAs: calcitriol and paricalcitol. Biochemical parameters, cardiac fibrosis, miRNA (miR-29b, miR-30c and miR-133b) levels in the heart and serum and expression of their target genes collagen I (COL1A1), matrix metalloproteinase 2 (MMP-2) and connective tissue growth factor (CTGF) in the heart were evaluated. RESULTS: Both VDRAs attenuated cardiac fibrosis, achieving a statistically significant difference in the paricalcitol-treated group. Increases in RNA and protein levels of COL1A1, MMP-2 and CTGF and reduced expression of miR-29b and miR-30c, known regulators of these pro-fibrotic genes, were observed in the heart of chronic renal failure (CRF) rats and were attenuated by both VDRAs. In serum, significant increases in miR-29b, miR-30c and miR-133b levels were observed in CRF rats, which were prevented by VDRA use. Moreover, vitamin D response elements were identified in the three miRNA promoters. CONCLUSIONS: VDRAs, particularly paricalcitol, attenuated cardiac fibrosis acting on COL1A1, MMP-2 and CTGF expression, partly through regulation of miR-29b and miR-30c. These miRNAs and miR-133b could be useful serum biomarkers for cardiac fibrosis and also potential new therapeutic targets.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Panizo S, Carrillo-López N, Naves-Díaz M, et al. Regulation of miR-29b and miR-30c by vitamin D receptor activators contributes to attenuate uraemia-induced cardiac fibrosis. Nephrol Dial Transplant. 2017. PMID: 28460073. doi:10.1093/ndt/gfx060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。